UK Markets closed

ERYTECH Pharma S.A. (0QSS.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
2.0700-0.0150 (-0.72%)
At close: 01:54PM GMT
Full screen
Previous close2.0850
Open2.0700
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.0700 - 2.0700
52-week range2.0700 - 2.0700
Volume964
Avg. volumeN/A
Market cap32.107M
Beta (5Y monthly)1.74
PE ratio (TTM)N/A
EPS (TTM)-3.1810
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2021

    Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2021. Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net

  • Globe Newswire

    ERYTECH to Participate in the Upcoming January Virtual Investor Conferences

    ERYTECH to Participate in the Upcoming January Virtual Investor Conferences Cambridge, MA (U.S.) and Lyon (France), January 3, 2022 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced their participation in upcoming investor conferences and invites investors to participate in one-on-one meetings: LifeSci Partners - 11th Annual Corporate Access Ev

  • Globe Newswire

    ERYTECH Announces $7.85 Million Registered Direct Offering

    ERYTECH Announces $7.85 Million Registered Direct Offering Lyon (France) and Cambridge, MA (U.S.), December 14, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP) (the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it has entered into a definitive agreement with Armistice, a health-care focused institutional and accredited investor, for the purchase and sale of 769,608 u